Clinical Trial Update: Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update of Myfortic (mycophenolate mofetil) in heart transplant patients with GI symptoms. The current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Heart Transplant Patients | Phase 3 | Status: UNKNOWN